Abstract:The ubiquitin-proteasome pathway plays a pivotal role in the regulation of cellular protein processing and degradation. Proteasome inhibitors (PIs) have enormous potential to treat multiple myeloma, solid tumors, parasites, inflammation, and immune diseases, which is spurring the development of new types of PIs with enhanced efficacy, fewer side effects, and reduced drug resistance. Nevertheless, virtual screening for covalent PIs has rarely been reported because calculating the covalent binding energy is a challenging task. The aim of this study was to discover new covalent inhibitors of the 20S proteasome. The structures of PIs were manually divided into two parts: a noncovalent binding part resulting from virtual screening, and an epoxyketone group that was pre-selected as a covalent binding part. The SPECS database was screened by noncovalent docking and a pharmacophore model built with the 20S proteasome. After validating the covalent conjugation, 88 hits with epoxyketone were covalently docked into the 20S proteasome to analyze the intermolecular interactions. Four compounds were selected after multiple filtration and validations. Molecular dynamics simulations were performed to check the stability of the noncovalent and covalent docked ligand-enzyme complexes and investigate the interaction patterns of the screened inhibitors. Finally, two compounds with novel aromatic backbones, reasonable interactions, and stable covalent binding modes were retained. These compounds can serve as potential hits for further biological evaluation.

Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.

Small organic molecules targeting PCAF bromodomain as potent inhibitors of HIV-1 replication

Discovery of Pyrrolo[3,2-d]pyrimidin-4-one Derivatives As a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain

Structure based identification and biological evaluation of novel and potent inhibitors of PCAF catalytic domain

A New Assay Based on Fluorescence Resonance Energy Transfer to Determine the Binding Affinity of Bcl-xLInhibitors

An Affinity-Based Fluorescence Polarization Assay for Protein Tyrosine Phosphatases.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors.

Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor.

Synthesis and structure-activity relationships of N - (3 - (1H-imidazol-2-yl) phenyl) - 3-phenylpropionamide derivatives as a novel class of covalent inhibitors of p97/VCP ATPase

A Small-Molecule Probe for Monitoring Binding to Prolyl Hydroxylase Domain 2 by Fluorescence Polarisation.

In Situ Inhibitor Synthesis and Screening by Fluorescence Polarization: an Efficient Approach for Accelerating Drug Discovery.

Design, Synthesis and Biological Evaluation of Novel 5-Fluoro-1h-benzimidazole-4-carboxamide Derivatives As Potent PARP-1 Inhibitors.

A Fluorescence Polarization Biophysical Assay for the Naegleria DNA Hydroxylase Tet1.

Discovery of Novel Pyrimidine Molecules Containing Boronic Acid As VCP/p97 Inhibitors.

Discovery of Novel Covalent Proteasome Inhibitors Through a Combination of Pharmacophore Screening, Covalent Docking, and Molecular Dynamics Simulations.

Screening, Synthesis, Crystal Structure, and Molecular Basis of 6-Amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles As Novel AKR1C3 Inhibitors.

Design, synthesis and biological evaluation of novel, orally bioavailable pyrimidine-fused heterocycles as influenza PB2 inhibitors.

Caspase-1 Specific Light-Up Probe with Aggregation-Induced Emission Characteristics for Inhibitor Screening of Coumarin-Originated Natural Products.

Design, Synthesis, and Biological Evaluation of Novel HIV-1 Protease Inhibitors Containing Pyrrolidine-Derived P2 Ligands to Combat Drug-Resistant Variant

Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association.